Clinical Trial Detail

NCT ID NCT02514083
Title A Phase II Study Using Ibrutinib and Short-Course Fludarabine in Previously Untreated Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors National Heart, Lung, and Blood Institute (NHLBI)
Indications

CLL/SLL

chronic lymphocytic leukemia

Therapies

Fludarabine + Ibrutinib

Age Groups: adult senior

No variant requirements are available.